Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Actelion reports ‘need for early PAH diagnosis and treatment’

Actelion reports ‘need for early PAH diagnosis and treatment’

4th September 2007

Actelion has announced the results of a phase IIIb clinical trial of Tracleer (bosentan) in patients with mildly symptomatic pulmonary arterial hypertension (PAH), with these trial results underlining the need for early diagnosis and treatment of the condition.

Presented at the European Society of Cardiology congress in Vienna, the six-month study involved World Health Organisation functional class II PAH patients.

In the trial, patients administered with bosentan exhibited a significant improvement of quality of life indices when compared to those receiving placebo, in addition to showing a lower incidence of worsening functional class.

The compound was also shown to lower pulmonary vascular resistance in addition to a number of other key haemodynamic measurements.

Jean-Paul Clozen, chief executive officer of Actelion, said: “The results of the Early study reinforce our understanding of PAH as a progressive and serious disease that needs to be diagnosed and treated in the early stages.”

He added that the study marked the third randomised controlled trial of the compound that showed the drug to have a significant effect on the time to clinical worsening – an indication of the progression of the disease.

In June 2007, Actelion announced that Tracleer had been granted marketing approval from the European Commission as a treatment for new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.